mCRPC: early PRO data favor abiraterone in AQUARiUS

  • Thiery-Vuillemin A & al.
  • ESMO Open
  • 01.01.2018

  • von Deepa Koli
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Initial analysis of ongoing AQUARiUS trial indicates abiraterone acetate plus prednisone (AAP) provides significant benefit in cognitive outcome and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) vs enzalutamide.
  • No significant difference was observed in pain outcome.

Why this matters

  • Both treatments improved survival of mCRPC; differences in patient-reported outcomes (PROs) may help physicians choose the most appropriate treatment in specific patients.
  • Final data are needed to confirm initial findings.

Study design

  • AQUARiUS is an ongoing, 2-cohort, phase 4 European study.
  • 105 patients were evaluated at 3 months: 46 patients were treated with AAP and 59 received enzalutamide.
  • Funding: Janssen Pharmaceutica N.V.

Key results

  • At 3 months, AAP vs enzalutamide significantly improved:
    • Cognitive impairment (Functional Assessment of Cancer Therapy-Cognitive Function): mean difference (MD), 6.64; P=.025.
    • Cognitive functioning (Quality of Life Questionnaire-C30 [QLQ-C30]): MD, 11.82; P=.035.
    • Usual level of fatigue (Brief Fatigue Inventory-Short Form [BFI-SF]): MD, −1.41; P=.038.
    • Fatigue interference (BFI-SF): MD, −1.20; P=.036.
    • Current fatigue (BFI-SF): MD, −1.41; P=.017.
    • Worse level of fatigue (BFI-SF): MD, −1.63; P=.019.
    • Fatigue (QLQ-C30): MD, −16.20; P=.009.
    • Pain (QLQ-C30): MD, −13.59; P=.017.
  • No significant differences between cohorts were observed for pain (Brief Pain Inventory-Short Form) at any time-point.

Limitations

  • Observational study.